Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs
Cancer · 2025
DOI: 10.1002/cncr.70024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Hannah Burton und 16 weiteren Autor:innen. Beteiligte Einrichtung: Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cytarabine, Hospitalization, Consolidation Chemotherapy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Administration of intensive induction chemotherapy followed by consolidation with postremission high‐ or intermediate‐dose cytarabine (H/IDAC) remains a standard therapeutic approach in fit patients with nonadverse risk acute myeloid leukemia (AML). Historically, H/IDAC has been administered in the inpatient (IP) rather than outpatient (OP) setting given infection risk, transfusion and supportive care needs, and logistical challenges of OP treatment. However, the financial toxicity associated with IP chemotherapy hospitalization as well as risk of nosocomial infections and improvements in antimicrobial prophylaxis have highlighted the potential role for OP H/IDAC administration.
Methods
Accordingly, an OP H/IDAC treatment program was developed at Memorial Sloan Kettering Cancer Center in 2014 using an ambulatory pump system. To investigate the benefits and risks of this approach compared with standard IP H/IDAC administration, a retrospective single‐center cohort study was conducted of 198 adult patients with AML who received either IP (59) or OP (139) H/IDAC consolidation.
Results
In the OP‐treated group, this approach safely reduced hospitalization days per cycle (median, 0.8 vs 7.5, p < .001) without leading to increased incidence of hospitalization for febrile neutropenia (incidence rate ratio, 1.07, p = .8) or higher rate of major treatment complications. Total cost per cycle was significantly lower for the OP‐treated group (median, $14,244 compared to $36,688, p < .001).
Conclusions
In the largest cohort study of adult AML patients receiving OP H/IDAC, OP treatment administration was feasible, led to decreased hospital days and cost savings, and did not impact relapse free or overall survival compared to IP administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
- Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Bone Marrow Transplant and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Leora Boussi, Meira Yisraeli Salman
Förderung
- NCI NIH HHS
Zitieren
APA
Burton, H., Boussi, L., Nemirovsky, D., Derkach, A., Ciervo, J., Famulare, C., Chin, K. K., Valtis, Y., Yisraeli Salman, M., Patel, K., Shah, G. L., Goldberg, A. D., Geyer, M. B., Thompson, M. C., Tallman, M. S., Stein, E. M., & Cai, S. F. (2025). Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs. Cancer. https://doi.org/10.1002/cncr.70024
Vancouver
Burton H, Boussi L, Nemirovsky D, Derkach A, Ciervo J, Famulare C, et al. Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs. Cancer. 2025. doi:10.1002/cncr.70024
BibTeX
@article{Burton2025,
author = {Burton, Hannah and Boussi, Leora and Nemirovsky, David and Derkach, Andriy and Ciervo, Jenna and Famulare, Christopher and Chin, Kuo-Kai and Valtis, Yannis and Yisraeli Salman, Meira and Patel, Kishan and Shah, Gunjan L and Goldberg, Aaron D and Geyer, Mark B and Thompson, Meghan C and Tallman, Martin S and Stein, Eytan M and Cai, Sheng F},
title = {Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.70024}
}
EUVIMED